PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 93 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $202,382,784 | +21.9% | 5,840,773 | +1.8% | 0.96% | +27.2% |
Q1 2024 | $166,028,489 | +26.3% | 5,738,973 | +0.1% | 0.75% | +21.3% |
Q4 2023 | $131,490,480 | +44.7% | 5,734,430 | +5.3% | 0.62% | +45.6% |
Q3 2023 | $90,846,452 | -27.1% | 5,446,430 | +20.7% | 0.42% | -32.0% |
Q2 2023 | $124,605,697 | +107.2% | 4,511,430 | +72.5% | 0.62% | +90.5% |
Q1 2023 | $60,145,322 | +51.0% | 2,615,014 | -28.4% | 0.33% | +39.6% |
Q4 2022 | $39,842,087 | +29.4% | 3,651,887 | 0.0% | 0.24% | +39.1% |
Q3 2022 | $30,785,000 | +5.2% | 3,651,887 | -1.3% | 0.17% | +6.3% |
Q2 2022 | $29,272,000 | +9.0% | 3,700,608 | +226.2% | 0.16% | +22.3% |
Q1 2022 | $26,864,000 | -59.0% | 1,134,457 | -40.8% | 0.13% | -60.2% |
Q4 2021 | $65,566,000 | +54.7% | 1,917,134 | -19.9% | 0.33% | +65.2% |
Q3 2021 | $42,386,000 | -59.5% | 2,392,000 | +2.7% | 0.20% | -53.6% |
Q2 2021 | $104,556,000 | +66.5% | 2,329,680 | -3.9% | 0.43% | +36.9% |
Q1 2021 | $62,808,000 | +28.5% | 2,425,000 | 0.0% | 0.31% | +6.1% |
Q4 2020 | $48,888,000 | -9.1% | 2,425,000 | -11.8% | 0.29% | -21.0% |
Q3 2020 | $53,763,000 | +21.8% | 2,750,000 | +10.0% | 0.37% | +5.4% |
Q2 2020 | $44,150,000 | +316.9% | 2,500,000 | +66.7% | 0.35% | +287.9% |
Q1 2020 | $10,590,000 | +0.1% | 1,500,000 | 0.0% | 0.09% | +28.2% |
Q4 2019 | $10,575,000 | -41.3% | 1,500,000 | 0.0% | 0.07% | -47.8% |
Q3 2019 | $18,015,000 | -0.8% | 1,500,000 | 0.0% | 0.14% | +15.3% |
Q2 2019 | $18,165,000 | -19.3% | 1,500,000 | -16.2% | 0.12% | -30.2% |
Q1 2019 | $22,500,000 | +52.0% | 1,790,000 | -18.6% | 0.17% | +55.0% |
Q4 2018 | $14,804,000 | -35.9% | 2,199,674 | -1.9% | 0.11% | -19.9% |
Q3 2018 | $23,083,000 | +277.4% | 2,243,202 | +146.4% | 0.14% | +257.9% |
Q2 2018 | $6,117,000 | -29.7% | 910,229 | -10.2% | 0.04% | -36.7% |
Q1 2018 | $8,706,000 | -53.5% | 1,013,500 | +12.6% | 0.06% | -60.5% |
Q4 2017 | $18,720,000 | – | 900,000 | – | 0.15% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 2,449,183 | $84,864,191 | 21.18% |
Cannon Global Investment Management, LLC | 69,900 | $2,422,035 | 11.28% |
ADAR1 Capital Management, LLC | 1,603,932 | $55,576,244 | 10.49% |
Checkpoint Capital L.P. | 355,000 | $12,300,750 | 7.42% |
Fairmount Funds Management LLC | 931,890 | $32,289,989 | 3.65% |
BVF INC/IL | 3,319,290 | $115,013,399 | 3.22% |
RTW INVESTMENTS, LP | 5,286,404 | $183,173,899 | 2.84% |
Kynam Capital Management, LP | 800,000 | $27,720,000 | 2.14% |
683 Capital Management, LLC | 604,449 | $20,944,158 | 1.58% |
Birchview Capital, LP | 48,000 | $1,663,200 | 1.54% |